First Heartland Consultants’s Teva Pharmaceuticals TEVA Stock Holding History

First Heartland Consultants’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,058	Closed	-$254	–	334
2016 Q2	$254	Hold	5,058	–	–	0.03%	251
2016 Q1	$271K	Hold	5,058	–	–	0.1%	208
2015 Q4	$332K	Hold	5,058	–	–	0.13%	185
2015 Q3	$286K	Sell	5,058 -35	-0.7%	-$2.27K	0.12%	186
2015 Q2	$301	Buy	5,093 +35	+0.7%	+$2.16K	0.08%	189
2015 Q1	$315K	Hold	5,058	–	–	0.12%	185
2014 Q4	$291K	Hold	5,058	–	–	0.12%	186
2014 Q3	$272K	Hold	5,058	–	–	0.12%	187
2014 Q2	$265K	Sell	5,058 -90	-2%	-$4.6K	0.12%	191
2014 Q1	$272K	Hold	5,148	–	–	0.13%	183
2013 Q4	$206K	Buy	+5,148	New	+$203K	0.12%	175

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First Heartland Consultants's TEVA Position: Q3 2016 in Review

First Heartland Consultants sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 5,058 shares — an estimated $254 sold.

First Heartland Consultants first reported a position in TEVA in Q4 2013 and held it in 11 quarters. The position peaked at $332K in Q4 2015. 795 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

First Heartland Consultants reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
First Heartland Consultants sold 5,058 Teva Pharmaceuticals shares in Q3 2016, an estimated $254.
First Heartland Consultants first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 11 quarters.
First Heartland Consultants's Teva Pharmaceuticals position peaked at $332K in Q4 2015.
795 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on First Heartland Consultants's 13F filing for Q3 2016, filed 23 Nov 2016.